$0.60
+0.05 (+9.96%)
Open$0.57
Previous Close$0.55
Day High$0.62
Day Low$0.53
52W High$2.76
52W Low$0.55
Volume—
Avg Volume2.85M
Market Cap193.65M
P/E Ratio—
EPS$-0.57
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+2,416.5% upside
Current
$0.60
$0.60
Target
$15.22
$15.22
$10.64
$15.22 avg
$24.41
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 3.82M | 3.26M | 180.17M |
| Net Income | -76,525,086 | -58,674,882 | 5.71M |
| Profit Margin | -2,003.6% | -1,903.4% | 3.2% |
| EBITDA | -230,612,584 | -186,643,341 | 9.37M |
| Free Cash Flow | — | — | 5.00M |
| Rev Growth | +17.4% | +17.4% | +21.8% |
| Debt/Equity | 20.86 | 20.86 | 0.48 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |